Mankind PharmaQ2 FY25

Mankind Pharma Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,610P/E: 46.2Market Cap: ₹1.1L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Mankind Pharma expects volume growth to improve from recent muted levels (1.3% in Q2 versus closer to 2% in Q1), aiming to outperform IPM consistently.
  • Historically, volume growth was 4%-5%; the company hopes to return to this range over the next 2-3 years.
  • Chronic segment is a key growth driver, currently contributing 36% of revenue, with an aspiration to exceed 40% in the short term and over 50% long term.
  • Specialty and consumer care businesses have significant headroom and growth potential.
  • Exports and international markets, including BSV acquisition, are expected to deliver strong double-digit growth (15-20% internationally from FY26 onwards).
  • Overall revenue growth guidance remains double-digit.
  • Price erosion in some segments (e.g., emergency contraceptives) is a factor but volume remains intact.
  • Ongoing commercial excellence initiatives are aimed at boosting volume and sales further.

See what Mankind Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Mankind Pharma raised INR 10,000 crores in debt for the BSV acquisition, split into INR 5,000 crores of nonconvertible debentures (NCDs) and INR 5,000 crores of commercial papers (CPs) with varying tenures and interest rates.
  • The company has shareholder approval for a potential equity raise aimed at retiring a portion of this debt to maintain a net debt-to-EBITDA ratio below 2x by FY '26.
  • The proposed equity raise is expected to be close to INR 3,000 crores, pending formal Board approval.
  • Debt repayment strategies include retiring debt using proceeds from non-core asset monetization (hospitality units) targeted at around INR 600-650 crores.
  • Overall, the company aims to fully liquidate INR 10,000 crores debt within 3 years through a mix of QIP (equity), asset sales, and operating cash flows.

See what Mankind Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Q2 FY'25 capex spend was INR128 crores, about 4.2% of total revenue, aligning with guidance of 4%-5%.
  • The company aims to maintain this capex range in line with its growth strategy.
  • Post-acquisition of BSV, integration efforts are underway with a roadmap expected to complete in next 2 quarters, indicating potential strategic investments in synergy realization.
  • There are ongoing commercial excellence exercises to improve productivity and growth, implying investment in processes and possibly technology.
  • No explicit mention of new large-scale capex projects, but strategic focus includes expanding chronic therapy portfolio and specialty segments which may involve future capital allocation.
  • Non-core assets (hospitality units) are being liquidated to repay debt, reflecting a focus on optimizing capital structure rather than new investments currently.

Track Mankind Pharma — get its next earnings analysis in your feed

How does Mankind Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisMankind Pharma
Rev 3Mar 3

How does Mankind Pharma rank in Pharmaceuticals & Biotechnology?

Compare Mankind Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →